LGVN Longeveron

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call and Webcast Details:
    
Conference Call Number:    1.877.407.0789
Conference ID:    13752361
    
Call meTM Feature:  
Webcast:  
    

An archived replay of the webcast will be available on the “” section of the Company’s website following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit or follow Longeveron on , , and .

Investor and Media Contact:

Derek Cole

Investor Relations Advisory Solutions





EN
02/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Appoints Than Powell as Chief Business Officer Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company’s overall business strategy, Alzheimer’s disease program partnering efforts, and international strategy fo...

 PRESS RELEASE

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Cli...

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan drug designation, and Fast track designationLaromestrocel HLHS program addresses...

 PRESS RELEASE

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Per...

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025. Details for the Company’s corporate presentation: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ETLon...

 PRESS RELEASE

Longeveron® to Attend BIO International Convention 2025

Longeveron® to Attend BIO International Convention 2025 Focus on potential partnership and strategic opportunities for the Company’s stem cell therapy program for Alzheimer’s diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer’s diseaseInitiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer’s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportResults f...

 PRESS RELEASE

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone ...

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selecte...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch